Ipsen Biopharmaceuticals, Inc. (United States)

Ipsen is a global specialty-driven biopharmaceutical company focused on oncology, neuroscience, and rare diseases. Key products include Somatuline (lanreotide) for neuroendocrine tumors and acromegaly, Dysport (abobotulinumtoxinA) for movement disorders and aesthetics, Onivyde (irinotecan liposomal) for pancreatic cancer, and Cabometyx (cabozantinib) for kidney and liver cancers. Ipsen’s targeted therapeutics address serious conditions with limited treatment options.